Family-based Telemedicine vs. Inpatient Anorexia Nervosa Treatment (FIAT)

Summary

The FIAT study is funded by the Innovationsfonds of the German Ministry of Health via the DLR Project Management Agency. The study will be conducted in up to 21 hospitals across Germany and in collaboration with 10 German public health insurance companies. The primary aim of this study is to compare Family-Based Treatment delivered via telehealth (FBT) with inpatient multimodal therapy (IMT) with respect to treatment outcomes and health economic data. The results of the study will serve as a basis for the decision on the inclusion of FBT in the German S3 guidelines and the future reimbursement of FBT by public health insurances in Germany.

Conditions

• Anorexia Nervosa
• Anorexia in Adolescence

Interventions

BEHAVIORAL

Family based treatment

FBT is an intensive, manualized therapy in which the parents of those affected are closely involved in a resource-oriented manner by FBT-certified therapists. FBT takes place in 3 phases: in phase 1, the parents take responsibility for their child's weight gain. Phase 2 involves the gradual transfer of responsibility for eating back to the patient. Phase 3 focuses on individual issues of the children and adolescents, e.g. catching up on important developmental steps missed due to the illness.

BEHAVIORAL

Inpatient multimodal therapy

comprehensive, patient-oriented and multidisciplinary approach to address eating disorders following the S3 joint German treatment guidelines in specialized hospitals. Includes individual psychotherapy, family sessions, body-oriented therapy, nutritional counseling, group therapy sessions, relaxation techniques, mindfulness practices, and skills training. Targeted weight gain per week is at least 500g.

Sponsors & Collaborators

• Bielefeld University

  collaborator OTHER

• Techniker Krankenkasse

  collaborator OTHER

• BARMER

  collaborator OTHER

• AOK Niedersachsen

  collaborator UNKNOWN

• Mobil Krankenkasse

  collaborator UNKNOWN

• Meine Krankenkasse

  collaborator UNKNOWN

• Medicalnetworks CJ GmbH & Co.KG

  collaborator UNKNOWN

• AOK Baden-Württemberg

  collaborator INDUSTRY

• DAK Gesundheit

  collaborator OTHER

• BIG-direkt

  collaborator UNKNOWN

• mhplus

  collaborator UNKNOWN

• Bahn-BKK

  collaborator UNKNOWN

• OFFIS - Institut für Informatik

  collaborator UNKNOWN

• Prof. Daniel Le Grange, UCSF

  collaborator UNKNOWN

• Charite University, Berlin, Germany

  lead OTHER

Principal Investigators

• Christoph U Correll, MD · Charite University, Berlin, Germany

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

8 Years

Max Age

17 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-01-31

Primary Completion

2027-03-31

Completion

2027-12-31

Countries

• Germany

Study Locations